Phillip M. Pifer

Phillip M. Pifer

Auto-generated profile, based on publicly available information

Phillip M. Pifer

Department of Radiation Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
DMDavid P. Molkentine
David P. Molkentine
JMJessica Molkentine
Jessica Molkentine
KBKathleen A. Bridges
Kathleen A. Bridges
DVDavid R. Valdecanas
David R. Valdecanas
ADAnnika Dhawan
Annika Dhawan
HSHeath Devin Skinner
Heath Devin Skinner
Squamous cell carcinoma driven by human papillomavirus (HPV) is more sensitive to DNA-damaging therapies than its HPV-negative counterpart. Here, we show that p16, the clinically used surrogate for HPV positivity, renders cells more sensitive to radiotherapy via a ubiquitin-dependent signaling pathway, linking high levels of this protein to increased activity of the transcription factor SP1, increased HUWE1 transcription, and degradation of ubiquitin-specific protease 7 (USP7) and TRIP12. Activation of this pathway in HPV-positive disease led to decreased homologous recombination and improved response to radiotherapy, a phenomenon that can be recapitulated in HPV-negative disease using USP7 inhibitors in clinical development. This p16-driven axis induced sensitivity to PARP inhibition and potentially leads to “BRCAness” in head and neck squamous cell carcinoma (HNSCC) cells. Thus, these findings support a functional role for p16 in HPV-positive tumors in driving response to DNA damage, which can be exploited to improve outcomes in both patients with HPV-positive and HPV-negative HNSCC. Significance: In HPV-positive tumors, a previously undiscovered pathway directly links p16 to DNA damage repair and sensitivity to radiotherapy via a clinically relevant and pharmacologically targetable ubiquitin-mediated degradation pathway.

1 January 2019 in Molecular Immunology
Verified
Journal Article
Closed access
IMIan MacFawn
Ian MacFawn
HWHannah Wilson
Hannah Wilson
LSLuke Selth
Luke Selth
ILIan Leighton
Ian Leighton
ISIlya Serebriiskii
Ilya Serebriiskii
Steven M. FrischSteven M. Frisch
Steven M. Frisch

11 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PPPhillip M. Pifer
Phillip M. Pifer
LYLiangpeng Yang
Liangpeng Yang
MKManish Kumar
Manish Kumar
TXTongxin Xie
Tongxin Xie
MFMitchell Frederick
Mitchell Frederick
HSHeath Devin Skinner
Heath Devin Skinner
Purpose: Radiation and platinum-based chemotherapy form the backbone of therapy in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). We have correlated focal adhesion kinase (FAK/PTK2) expression with radioresistance and worse outcomes in these patients. However, the importance of FAK in driving radioresistance and its effects on chemoresistance in these patients remains unclear. Experimental Design: We performed an in vivo shRNA screen using targetable libraries to identify novel therapeutic sensitizers for radiation and chemotherapy. Results: We identified FAK as an excellent target for both radio- and chemosensitization. Because TP53 is mutated in over 80% of HPV-negative HNSCC, we hypothesized that mutant TP53 may facilitate FAK-mediated therapy resistance. FAK inhibitor increased sensitivity to radiation, increased DNA damage, and repressed homologous recombination and nonhomologous end joining repair in mutant, but not wild-type, TP53 HPV-negative HNSCC cell lines. The mutant TP53 cisplatin-resistant cell line had increased FAK phosphorylation compared with wild-type, and FAK inhibition partially reversed cisplatin resistance. To validate these findings, we utilized an HNSCC cohort to show that FAK copy number and gene expression were associated with worse disease-free survival in mutant TP53, but not wild-type TP53, HPV-negative HNSCC tumors. Conclusions: FAK may represent a targetable therapeutic sensitizer linked to a known genomic marker of resistance.

6 March 2022 in Clinical Oncology
Verified
Journal Article
Closed access
SJS. Jaishankar
S. Jaishankar
PPP.M. Pifer
P.M. Pifer
RBR. Bhargava
R. Bhargava
AKA. Keller
A. Keller
HMH.B. Musunuru
H.B. Musunuru
SBS. Beriwal
S. Beriwal

7 March 2018 in American Journal of Hospice and Palliative Medicine®
Verified
Journal Article
Open access
PDF file
PPPhillip M. Pifer
Phillip M. Pifer
MFMark K. Farrugia
Mark K. Farrugia
MMMalcolm D. Mattes
Malcolm D. Mattes
Background: Early palliative/supportive care (PSC) consultation and advance care planning (ACP) improve outcomes for patients with incurable cancer. However, PSC is underutilized in the United States. Objective: To examine philosophical differences among PSC, radiation oncology (RO), and medical oncology (MO) physicians in order to understand barriers to early PSC referral. Design: An electronic survey collected views of a nationwide cohort of health-care professionals regarding ACP and end-of-life care. Setting/Participants/Measurements: A subgroup analysis compared the responses from all 51 PSC, 178 RO, and 81 MO physician participants (12% response rate), using Pearson χ 2 and Mann-Whitney U tests for categorical and ordinal data, respectively. Results: More statistically significant differences were observed between RO-PSC (12 questions) and MO-PSC (12 questions) than RO-MO (4 questions). Both RO and MO were more likely than PSC physicians to believe doctors adequately care for emotional ( P < .001) and physical ( P < .001) needs of patients with an incurable illness. Both RO and MO were also less likely to believe that PSC physicians were helpful at addressing these needs ( P = .002 and <.001, respectively) or that patients’ awareness of their life expectancy leads to better medical ( P = .007 and .002, respectively) and personal ( P = .001 for each) decisions. Palliative/supportive care physicians felt that doctors are generally less successful at explaining/clarifying advanced life-sustaining treatments than RO ( P < .001) or MO ( P = .004). MO favored later initiation of ACP than either RO ( P = .006) or PSC physicians ( P = .004). Conclusions: Differences in perception of appropriate end-of-life care exist between oncologists and PSC physicians, suggesting a need for improved education and communication between these groups.

31 March 2023
Verified
Other
Open access
DMDavid P. Molkentine
David P. Molkentine
JMJessica Molkentine
Jessica Molkentine
KBKathleen A. Bridges
Kathleen A. Bridges
DVDavid R. Valdecanas
David R. Valdecanas
ADAnnika Dhawan
Annika Dhawan
HSHeath D. Skinner
Heath D. Skinner
Supplementary Data from p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade